Market Overview

Research and Markets: Biosimilars Advisory Service: Physician Perspectives on Erythropoietin Stimulating Agents, Insulin, and Human Growth Hormone

Share:
DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/rr5p3b/biosimilars) has announced the addition of Decision Resources, Inc's new report "Biosimilars Advisory Service: Physician Perspectives on Erythropoietin Stimulating Agents, Insulin, and Human Growth Hormone" to their offering.

Although biosimilar versions of erythropoietin stimulating agents (ESAs) and human growth hormone (hGH) have experienced a relatively slow uptake with variable enthusiasm in Europe, branded ESAs, insulins, and hGH represent significant sales targets that attract biosimilar manufacturers to this potentially lucrative market. Despite this considerable potential, biosimilar versions of ESAs, insulins, and hGH will experience varying degrees of market share penetration and commercial success in 2020.

Over the course of our 2010-2020 forecast period, we anticipate that biosimilar ESAs will gain the second-highest market share of any of the biosimilar classes expected to be on the market. We expect the markets for biosimilar insulin and biosimilar hGH will be less robust compared with other classes of biosimilar drugs. Nevertheless, new biosimilar versions of ESAs and insulins will save healthcare systems $1.7 billion in 2020 across the seven pharmaceutical markets we cover (United States, EU5 [France, Germany, Italy, Spain, United Kingdom], and Japan). Total sales across the G7 markets for biosimilar ESAs, insulins, and hGH are forecast to exceed $3.2 billion in 2020, but product-class-specific hurdles prevent more significant biosimilar erosion.

The primary research presented in this report is gathered from a quantitative, online, 40-minute survey with 77 endocrinologists and 77 nephrologists from the United States, France, and Germany.

Key Topics Covered:

1. Key Findings

2. Introduction and Methodology

3. Nephrologist Perspectives

Current Reimbursement of Biologics in Nephrology

Current Understanding of Biosimilars

Expectations for Biosimilar Trials

Attitudes of Key Stakeholders

Anticipated Initial Use of Biosimilars

Eventual Use of Biosimilars

Reasons for Current Slow Adoption of Biosimilars

4. Endocrinologist Perspectives

Current Reimbursement of Biologics in Endocrinology

Current Understanding of Biosimilars

Expectations for Biosimilar Trials

Attitudes of Key Stakeholders

Anticipated Initial Use of Biosimilars

Eventual Use of Biosimilars

Reasons for Current Slow Adoption of Biosimilars

5. Market Forecast

Overview of Biosimilar Erosion Across Major Markets

Forecast Assumptions

Erythropoietin-Stimulating Agents (ESAs)

Insulin

Human Growth Hormone (hGH)

For more information visit http://www.researchandmarkets.com/research/rr5p3b/biosimilars

Source: Decision Resources, Inc

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Healthcare and Medical Devices, Pharmaceuticals

View Comments and Join the Discussion!